The biotech industry in Malaysia has emerged as a vital component of the nation’s economic development strategy, contributing significantly to economic diversification and sustainable growth. The sector drives innovation, creates high-value jobs, enhances competitiveness and spans crucial sectors like healthcare, agriculture, and industrial biotechnology.
We explore the emergence of biotechnology and nature’s influence on innovations in Southeast Asia
Understanding the key trends within the sector is essential for emerging biotech startups in Malaysia. This comprehension allows startups to tailor their strategies to align with technological advancements, regulatory shifts, and evolving market demands.
Growing government support and investment
The government’s unwavering commitment to the biotechnology sector is evident in its provision of substantial financial support and strategic initiatives. Notably, the BioAgrotech & BioPharmaceutical Employability and Entrepreneurship Specialised Training programme (BeST 2.0), organised by the Malaysian Bioeconomy Development Corporation, is a testament to this commitment.
This six-month program aims to boost the employability of graduates by providing them with essential industry skills and experiences in biotechnology, biotech-based industries, and related sectors. The Bio-based Accelerator (BBA) programme also supports the sector’s startups, micro-businesses, and large companies by infusing science and technology into their operations. It announced an additional RM5 million in funding for the BBA programme to boost local biotech companies and attract domestic and international players to this high-value, high-tech sector, ensuring a stable and supportive environment for the industry.
Rise of innovative biomedical solutions
In Malaysia, about 40% of the detection of new breast cancer cases diagnosed annually occur at a very late stage, with a five-year survival rate of nearly 60% for Stage 3 cases and 23% for Stage 4 cases. Duopharma Biotech, one of the region’s largest pharmaceutical companies, addresses this problem by developing a groundbreaking breast cancer screening technology through a partnership with US-based femtech company UE LifeSciences.
Its device, requiring minimal training, efficiently identifies and triages clinically relevant breast lumps in asymptomatic patients, brings standardisation to clinical breast examinations, and securely stores data in the cloud for easy follow-up. Its effectiveness in detecting breast cancer has been validated through several independent clinical studies worldwide, leading to regulatory approvals in over 12 countries.
Collaboration and ecosystem development
Collaborations among startups, research institutions, universities, and established companies facilitated by the Bioeconomy Corporation significantly strengthen the Malaysian biotech ecosystem. This agency, operating under the Ministry of Science, Technology, and Innovation (MOSTI) and owned by the Ministry of Finance Incorporated, is pivotal in accelerating the commercialisation of research findings and boosting industry productivity and competitiveness.
Guided by the National Biotechnology Policy 2.0, Bioeconomy Corporation’s broad mandates include policy advocacy, industry empowerment, and promoting foreign direct investments. It is crucial in creating a conducive environment for innovation, pushing local bio-based companies up the value chain, and implementing global strategies.
Leveraging technology for sustainable agricultural practices
Many of the country’s biotech startups use advanced technologies to enhance sustainable agricultural practices, tackle environmental issues, and boost food production efficiency. Urban Farm Tech, for instance, specialises in designing and implementing sustainable urban farming systems that use hydroponics, aquaponics, and IoT technologies.
The company aims to create self-sustaining communities equipped with modern urban agricultural techniques. Urban Farm Tech offers various services, including consulting on farm layout, crop selection, and marketing strategies, as well as providing educational programs on sustainable practices. The company has won recognition for its efforts to reduce water usage, eliminate the use of pesticides, and maximise crop yields, significantly enhancing the safety of the commercial food chain.
Exploitation of rich biodiversity for biopharmaceuticals
Malaysia’s rich biodiversity offers a unique platform for developing biopharmaceuticals, with new ventures capitalising on the diverse natural resources available in the nation’s rainforests and marine environments. The rapid increase in non-communicable diseases (NCDs), which pose significant challenges to the healthcare system, underscores the urgency of utilising this biodiversity.
The National Health and Morbidity Survey 2019 highlighted that NCDs accounted for 71% of premature deaths, a situation exacerbated by the COVID-19 pandemic. In response to these challenges, AstraZeneca partnered with Sunway University in 2021 to establish Malaysia’s first Health Innovation Hub (HIH) as part of its A Catalyst Network. This initiative aims to foster partnerships with local healthcare innovators, providing them with the necessary platforms and tools to create sustainable ecosystems and propel digital health innovation.
The current trends shaping the biotech industry in Malaysia are a testament to the innovative and dynamic nature of biotech startups in the region. These enterprises are responding to immediate health and environmental challenges and actively shaping a sustainable future through strategic collaborations, technological advancements, and exploiting the country’s rich biodiversity. Economically, these trends attract foreign investment and foster job creation, which enhances overall economic stability and growth.
As biotech startups in Malaysia continue to evolve and expand their capabilities, they contribute to the diversification and resilience of the country’s economy, aligning with the national goals for development and prosperity.